Extended community testing constitutes one of the main strategic pillars in controlling theCOVID-19 pandemic. Reverse transcription PCR (RT-PCR) targeting the SARS-CoV-2 genome onnasopharyngeal swab samples is currently the reference test. While displaying excellent analyticalsensitivity and specificity, this test is costly, often requires a substantial turnaround time, and, moreimportantly, is subject to reagent and other material shortages. To complement this technology,rapid antigen tests have been developed and made available worldwide, allowing cheap, quick, anddecentralized SARS-CoV-2 testing. The main drawback of these tests is the reduced sensitivity whenRT-PCR is the gold standard. In this study, we evaluate Visby an innovative, portable, easy-to-use RT-PCR point-of-care (POC) diagnostic device. Our retrospective analysis shows that overall, comparedto the Cobas 6800 RT-qPCR assay (Roche), this RT-PCR POC technology detects SARS-CoV-2 RNAwith 95% sensitivity (95%CI = 86.3–99%) and 100% specificity (95% CI = 80.5–100%). For sampleswith cycle-threshold values below 31, we observed 100% sensitivity (95% CI = 66.4–100%). Whileshowing an analytical sensitivity slightly below that of a standard RT-qPCR system, the evaluatedVisby RT-PCR POC device may prove to be an interesting diagnostic alternative in the COVID-19pandemic, potentially combining the practical advantages of rapid antigen tests and the robustanalytical performances of nucleic acid detection systems.